Recent News

• 08.12.2025 - APYX MEDICAL CORPORATION TO PARTICIPATE IN THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE
• 08.07.2025 - APYX MEDICAL CORPORATION REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
• 08.07.2025 - APYX MEDICAL EXPANDS GLOBAL SALES LEADERSHIP WITH STRATEGIC HIRES TO SUPPORT AYON LAUNCH AND ACCELERATED GROWTH
• 08.07.2025 - APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
• 07.28.2025 - APYX MEDICAL CORPORATION ANNOUNCES LAUNCH OF RENUVION® IN CHINA
• 07.24.2025 - APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2025 FINANCIAL RESULTS ON AUGUST 7, 2025
• 06.02.2025 - Renuvion® Brings Real Transformations to the Runway at Miami Swim Week

Recent Filings

• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - 8-K Current report
• 06.25.2025 - DEF 14A Other definitive proxy statements
• 06.13.2025 - PRE 14A Other preliminary proxy statements
• 05.30.2025 - SD Specialized disclosure report
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2025 - 4 Statement of changes in beneficial ownership of securities